2004
Determination of Midazolam from Perfuse Medium as a Probe Substrate of Cytochrome P450 3A1/2 Activity in Rats
JUŘICA, Jan; Miroslav DOSTÁLEK; Josef TOMANDL a Eva HADAŠOVÁZákladní údaje
Originální název
Determination of Midazolam from Perfuse Medium as a Probe Substrate of Cytochrome P450 3A1/2 Activity in Rats
Název česky
STANOVENÍ MIDAZOLAMU Z PERFUZNÍHO MEDIA JAKO MARKERU CYTOCHROMU P450 3A1/2 U POTKANA
Název anglicky
DETERMINATION OF MIDAZOLAM FROM PERFUSE MEDIUM AS A PROBE SUBSTRATE OF CYTOCHROME P450 3A1/2 ACTIVITY IN RATS
Autoři
Vydání
Olomouc, ACTA UNIVERISTATIS PALACKIANAE OLOMUCENSIS FACULTAS RERUM NATURALIUM, od s. 218-218, 1 s. 2004
Nakladatel
Univerzita Palackého Olomouc
Další údaje
Jazyk
čeština
Typ výsledku
Stať ve sborníku
Obor
30104 Pharmacology and pharmacy
Stát vydavatele
Česká republika
Utajení
není předmětem státního či obchodního tajemství
Označené pro přenos do RIV
Ano
Kód RIV
RIV/00216224:14110/04:00010735
Organizační jednotka
Lékařská fakulta
ISBN
80-244-0882-1
Klíčová slova anglicky
Midazolam; CYP-450
Změněno: 3. 12. 2008 20:29, doc. RNDr. Josef Tomandl, Ph.D.
V originále
The aim of the project was to develop HPLC method for determination of midazolam and its three metabolites, 1- and 4-hydroxymidazolam and 1,4-dihydroxymidazolam from perfuse rat liver medium. Hydroxylation of midazolam is used as a valuable tool for measurement of metabolic activity of the 3A1/2 isoform of cytochrome P-450 in rats (CYP3A1/2)This method is simple, rapid, sensitive and applicable for modeling and description of possible pharmacological interactions on rat CYP3A1/2.
Anglicky
The aim of the project was to develop HPLC method for determination of midazolam and its three metabolites, 1- and 4-hydroxymidazolam and 1,4-dihydroxymidazolam from perfuse rat liver medium. Hydroxylation of midazolam is used as a valuable tool for measurement of metabolic activity of the 3A1/2 isoform of cytochrome P-450 in rats (CYP3A1/2)This method is simple, rapid, sensitive and applicable for modeling and description of possible pharmacological interactions on rat CYP3A1/2 or it`s human orthologue CYP3A4/5, respectively.